RECRUITING

Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow. Primary Objective • To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls. Secondary Objective * To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors. * To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors.

Official Title

Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors

Quick Facts

Study Start:2025-02
Study Completion:2028-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06819475

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Survivor- or Control-Participant is age 18 years old or older at time of consent and enrolled in SJLIFE.
  2. * Survivor- Participant is childhood ALL survivor
  3. * Survivor- or Control Participant has low muscle mass as defined by relative lean mass z-score of less than or equal to -1 SD (lean mass divided by height in meters squared).
  4. * Survivor- or Control-Participant is able and willing to give informed consent
  1. * Survivor-Participant has history of cranial radiation.
  2. * Survivor- or Control-Participant has implanted medical devices or metal that would interfere with MRI or MRS
  3. * Female Survivor- or Control-Participant is pregnant.
  4. * Survivor- or Control-Participant is taking anticoagulants (e.g. aspirin, apixaban, coumadin, edoxaban, rivaroxaban)
  5. * Survivor- or Control-Participant weighs more than 300 pounds.
  6. * Survivor- or Control-Participant is allergic to local anesthetic (i.e., lidocaine, bupivacaine).
  7. * Survivor- or Control-Participant cannot lie flat on his/her back for 90 minutes or longer
  8. * Survivor- or Control-Participant has a current history of peripheral motor neuropathy.

Contacts and Locations

Study Contact

Puneet Bagga, PhD
CONTACT
866-278-5833
referralinfo@stjude.org
Puneet Bagga, PhD
CONTACT
referralinfo@stjude.org

Principal Investigator

Puneet Bagga, PhD
PRINCIPAL_INVESTIGATOR
St. Jude Children's Research Hospital

Study Locations (Sites)

St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
United States

Collaborators and Investigators

Sponsor: St. Jude Children's Research Hospital

  • Puneet Bagga, PhD, PRINCIPAL_INVESTIGATOR, St. Jude Children's Research Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02
Study Completion Date2028-01

Study Record Updates

Study Start Date2025-02
Study Completion Date2028-01

Terms related to this study

Keywords Provided by Researchers

  • Survivor
  • Acute Lymphoblastic Leukemia
  • Adult
  • ALL
  • Healthy Volunteer

Additional Relevant MeSH Terms

  • Childhood Cancer
  • Muscle Weakness